内容紹介
A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient
Summary
A 60s-year-old woman with metastatic colorectal cancer was treated using mFOLFOX6 plus bevacizumab. Zoledronic acid was also administered owing to the presence of bone metastasis. The patient was admitted to our hospital with progressive hypokalemia, hypocalcemia, hypophosphatemia, and proximal renal tubular dysfunction. A diagnosis of Fanconi syndrome was made, and was believed to be induced by zoledronic acid treatment. This treatment was discontinued, and the patient's renal tubular function recovered. Denosumab was subsequently administered to treat the bone metastasis, and no renal tubular dysfunction occurred. It was possible to continue chemotherapy, and a complete response was obtained. Fanconi syndrome induced by zoledronic acid is rare, but it may hinder chemotherapy. Therefore, monitoring renal tubular function is recommended during therapy with zoledronic acid.
要旨
症例は60歳台,女性。S状結腸癌,多発骨転移と診断し,化学療法およびゾレドロン酸投与を施行した。経過中,電解質異常,尿所見の異常を認め,ゾレドロン酸が原因のFanconi症候群と診断した。薬剤中止により電解質,尿所見は正常化した。大腸癌に関しては化学療法を継続可能であり,完全奏効が得られた。大腸癌骨転移例に対して投与したゾレドロン酸が原因となったFanconi症候群を経験したので報告する。
目次
Summary
A 60s-year-old woman with metastatic colorectal cancer was treated using mFOLFOX6 plus bevacizumab. Zoledronic acid was also administered owing to the presence of bone metastasis. The patient was admitted to our hospital with progressive hypokalemia, hypocalcemia, hypophosphatemia, and proximal renal tubular dysfunction. A diagnosis of Fanconi syndrome was made, and was believed to be induced by zoledronic acid treatment. This treatment was discontinued, and the patient's renal tubular function recovered. Denosumab was subsequently administered to treat the bone metastasis, and no renal tubular dysfunction occurred. It was possible to continue chemotherapy, and a complete response was obtained. Fanconi syndrome induced by zoledronic acid is rare, but it may hinder chemotherapy. Therefore, monitoring renal tubular function is recommended during therapy with zoledronic acid.
要旨
症例は60歳台,女性。S状結腸癌,多発骨転移と診断し,化学療法およびゾレドロン酸投与を施行した。経過中,電解質異常,尿所見の異常を認め,ゾレドロン酸が原因のFanconi症候群と診断した。薬剤中止により電解質,尿所見は正常化した。大腸癌に関しては化学療法を継続可能であり,完全奏効が得られた。大腸癌骨転移例に対して投与したゾレドロン酸が原因となったFanconi症候群を経験したので報告する。